ArticleEuropean journal of nuclear medicine and molecular imaging2021
Equivalent tumor detection for early and late FAPI-46 PET acquisition.
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07215182 ([68Ga]Ga-FAPI PET/CT for Response Evaluation During Immune Checkpoint Inhibitor Therapy in Malignant Melanoma), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
[68Ga]Ga-FAPI PET/CT for Response Evaluation During Immune Checkpoint Inhibitor Therapy in Malignant Melanoma
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?Contrast media & molecular imaging · 2022Pooled it
- State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Head-to-head comparison ofAnnals of nuclear medicine · 2025Trial
- Osteoarthritis and fibroblast activation: an imaging study assessing feasibility and reliability of whole-bodySkeletal radiology · 2026Article
- Article
- Exploratory evaluation of earlyEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Bridging Research and Clinical Practice: Automated [Pharmaceuticals (Basel, Switzerland) · 2026Article
- Potential value of [European journal of nuclear medicine and molecular imaging · 2026Article
- Early image acquisitionEuropean journal of nuclear medicine and molecular imaging · 2026Article
- A prospective comparison of early versus lateScientific reports · 2025Article
- Optimizing [EJNMMI research · 2025Article
- Multitracer comparison of gold standard PSMA-PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- Assessment of fully quantitative and simplified methods for analysis of [European journal of nuclear medicine and molecular imaging · 2025Article
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- [68Ga]Ga-FAPI-46 PET/CT for Staging Suspected/Confirmed Lung Cancer: Results on the Surgical Cohort Within a Monocentric Prospective Trial.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The earliest optimal timing for total-bodyEuropean radiology · 2024Article
- Development and application of a fully automatic multi-function cassette module Mortenon M1 for radiopharmaceutical synthesis.Annals of nuclear medicine · 2024Article
- Comparative analysis of two timepoints on [European journal of hybrid imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPositron emission tomography (PET) using small ligands of the fibroblast activation protein (FAP) was recently introduced. However, optimal uptake time has not been defined yet. Here, we systematically compare early (~ 10 min p.i.) and late (~ 60 min p.i.) FAPI-46 imaging in patients with various types of cancer.
methodsThis is a retrospective single-institutional study. Imaging was performed at the Essen University Hospital, Germany. A total of 69 patients who underwent dual time-point imaging for either restaging (n = 52, 75%) or staging (n = 17, 25%) of cancer were included. Patients underwent PET with two acquisitions: early (mean 11 min, SD 4) and late (mean 66 min, SD 9). Mean injected activity was 148 MBq (SD 33).
resultsIn total, 400 lesions were detected in 69 patients. Two of 400 (0.5%) lesions were only seen in early time-point imaging but not in late time-point imaging. On a per-patient level, there was no significant difference between SUV
conclusionIn conclusion, early (~ 10 min p.i.) versus late (~ 60 min p.i.) FAPI-46 imaging resulted in equivalent lesion uptake and tumor detection. For improved feasibility and scan volume, we implement early FAPI-46 PET in future clinical and research protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.